These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38844407)

  • 1. Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma.
    Zhu C; Zhang C; Wang S; Xun Z; Zhang D; Lan Z; Zhang L; Chao J; Liang Y; Pu Z; Ning C; Sang X; Yang X; Wang H; Jiang X; Zhao H
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38844407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microecological regulation in HCC therapy: Gut microbiome enhances ICI treatment.
    Liu X; Li S; Wang L; Ma K
    Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167230. PubMed ID: 38734322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.
    Mao J; Wang D; Long J; Yang X; Lin J; Song Y; Xie F; Xun Z; Wang Y; Wang Y; Li Y; Sun H; Xue J; Song Y; Zuo B; Zhang J; Bian J; Zhang T; Yang X; Zhang L; Sang X; Zhao H
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34873013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome.
    Temraz S; Nassar F; Kreidieh F; Mukherji D; Shamseddine A; Nasr R
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.
    Lee PC; Wu CJ; Hung YW; Lee CJ; Chi CT; Lee IC; Yu-Lun K; Chou SH; Luo JC; Hou MC; Huang YH
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35738801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma.
    Zheng Y; Wang T; Tu X; Huang Y; Zhang H; Tan D; Jiang W; Cai S; Zhao P; Song R; Li P; Qin N; Fang W
    J Immunother Cancer; 2019 Jul; 7(1):193. PubMed ID: 31337439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors: A Chinese population-based study.
    Li L; Ye J
    Medicine (Baltimore); 2020 Sep; 99(37):e21788. PubMed ID: 32925716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors.
    Abenavoli L; Montori M; Svegliati Baroni G; Argenziano ME; Giorgi F; Scarlata GGM; Ponziani F; Scarpellini E
    Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629716
    [No Abstract]   [Full Text] [Related]  

  • 9. Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma.
    Ji JH; Ha SY; Lee D; Sankar K; Koltsova EK; Abou-Alfa GK; Yang JD
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients.
    Zhang C; Wang J; Sun Z; Cao Y; Mu Z; Ji X
    Cancer Sci; 2021 Aug; 112(8):3005-3017. PubMed ID: 34028936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitor resistance in hepatocellular carcinoma.
    Wang Z; Wang Y; Gao P; Ding J
    Cancer Lett; 2023 Feb; 555():216038. PubMed ID: 36529238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma.
    Shen YC; Lee PC; Kuo YL; Wu WK; Chen CC; Lei CH; Yeh CP; Hsu C; Hsu CH; Lin ZZ; Shao YY; Lu LC; Liu TH; Chen CH; Wu MS; Huang YH; Cheng AL
    J Hepatocell Carcinoma; 2021; 8():809-822. PubMed ID: 34336726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.
    Lee PC; Chao Y; Chen MH; Lan KH; Lee IC; Hou MC; Huang YH
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32863270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti-PD-1 based immunotherapy in hepatocellular carcinoma.
    Wu H; Zheng X; Pan T; Yang X; Chen X; Zhang B; Peng L; Xie C
    Int J Cancer; 2022 Oct; 151(8):1321-1334. PubMed ID: 35579980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis.
    Xu H; Cao D; Zheng Y; Zhou D; Chen X; Lei J; Ge W; Xu X
    Int Immunopharmacol; 2021 Nov; 100():108135. PubMed ID: 34530205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect.
    Xia L; Zhu X; Wang Y; Lu S
    Cancer Lett; 2024 Aug; 598():217123. PubMed ID: 39033797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors.
    Shaikh FY; White JR; Gills JJ; Hakozaki T; Richard C; Routy B; Okuma Y; Usyk M; Pandey A; Weber JS; Ahn J; Lipson EJ; Naidoo J; Pardoll DM; Sears CL
    Clin Cancer Res; 2021 May; 27(9):2571-2583. PubMed ID: 33593881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
    Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
    BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma.
    Mohr R; Jost-Brinkmann F; Özdirik B; Lambrecht J; Hammerich L; Loosen SH; Luedde T; Demir M; Tacke F; Roderburg C
    Front Immunol; 2021; 12():652172. PubMed ID: 33859646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice.
    Pinato DJ; Marron TU; Mishra-Kalyani PS; Gong Y; Wei G; Szafron D; Sharon E; Saeed A; Jun T; Dharmapuri S; Naqash AR; Peeraphatdit T; Gampa A; Wang Y; Khan U; Muzaffar M; Navaid M; Lee CJ; Lee PC; Bulumulle A; Yu B; Paul S; Nimkar N; Bettinger D; Hildebrand H; Abugabal YI; Pressiani T; Personeni N; D'Alessio A; Kaseb AO; Huang YH; Ang C; Schneider J; Pillai A; Rimassa L; Goldberg KB; Pazdur R; Theoret M; Lemery S; Fashoyin-Aje '; Cortellini A; Pelosof L
    Eur J Cancer; 2021 Nov; 157():140-152. PubMed ID: 34508996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.